An efficient and targeted gene integration system for high-level antibody expression
Abstract
Random integration linking genomic amplification has been used to generate desired cell lines for stable and high-level expressing recombinant antibodies. But this technique is laborious, and the expression level is unpredictable due to position effects. Here, we have constructed a cell-vector system for high-level antibody expression using an FRT/FLP strategy to overcome position effects. The key is to target the FRT sequence to chromosomal locations where there is a high rate of transcription and gene amplification, and the amplified genes can be maintained. To screen desired loci with high transcriptional activity and amplifiable capacity, dual weakened markers (selectable galactosidase and amplifiable dihydrofolate reductase, DHFR) and the FRT sequence were synchronously cloned into a plasmid. After transfection of a Chinese hamster ovary host cell line with this plasmid, we selected 20 candidate cell lines from 721 individual clones. An antibody gene-targeting vector carrying an FRT-fused hygromycin gene was constructed to target antibody genes into the chromosomal FRT site by FLP recombinase. Three out of 20 cell lines can be used as host cells for site-specific recombination. By using southern blot and fluorescence in situ hybridization (FISH), a candidate engineered cell line, number 37, was chosen. It contains a single FRT-tagged locus in its genome. FISH analysis indicated that the antibody genes were all located at the original FRT-tagged locus in the genome of the…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RMCE technology had good success in increasing the success rate and reducing timelines for generation of stable industrial-grade CHO cell lines stably expressing monoclonal antibodies.
“This technology had good success in increasing the success rate and reducing timelines for the generation of stable industrial-grade CHO cell lines stably expressing monoclonal antibodies (Kito et al., 2002;Huang et al., 2007;Zhang et al., 2015).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Huang et al., 2007
Several recombinases have been used for targeted site approaches, among which Cre/Lox and Flp/FRT were mostly utilized.
“As first generation tools, several recombinases have been used for targeted site approaches, among which the Cre/Lox and the Flp/FRT were mostly utilized (Kito et al., 2002;Huang et al., 2007;Kim et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Huang et al., 2007
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
Guidelines to cell engineering for monoclonal antibody production
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.10.002 · Cited by 178 · see citing works
Fan, L., Frye, C. C., & Racher, A. J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.56 · Cited by 35 · see citing works
- Authors
- Huang, Y., Li, Y., Wang, Y. G., Gu, X., Wang, Y., & Shen, B. F.
- Affiliations
- Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (CN)
- Corresponding author
- Shen, Bei Fen
- Venue
- Journal of Immunological Methods
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 322
- Issue
- 1-2
- Pages
- 28-39
- ISSN
- 0022-1759 (ISSN-L)
- OpenAlex
- W1982609556
- Cited by
- 75
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 7 · 2012: 4
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Immunological Methods (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant antibody production, gene amplification, position effect, CHO cells, dihydrofolate reductase, galactosidase, hygromycin, fluorescence in situ hybridization
- MeSH terms
- Animals, Antibodies, Cricetulus, DNA, Female, Gene Amplification, Genetic Engineering, Cricetinae, Plasmids, Recombinant Proteins, Transcription, Genetic, Gene Expression, CHO Cells, In Situ Hybridization, Fluorescence, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review